tirzepatide and crohn's Patients with stable inflammatory bowel disease (IBD) comorbid obesity and/or diabetes who started GLP-1 receptor agonists (semaglutide or tirzepatide) alongside ongoing treatment did not have a lower risk for the relapse Alimentary Pharmacology & Therapeutics |

Rare : A severe allergic reaction (anaphylaxis/angioedema) symptoms include breathing problems, swelling in the face and mouth, wheezing, difficulty swallowing, pale and cold skin, dizziness and weakness

For people with type 2 diabetes, there is additional evidence of renal benefit from use of dapagliflozin in populations with eGFR down to 15 mL/min/1.73 m 2 and lower uACR values from DECLARE-TIMI 58 and DAPA-HF trials (NICE, 2022c)

We have also shown that they prevent the build-up of proteins associated with Alzheimers disease (at least in animal models), but the effect appears to be protective against future disease, rather than active disease. Key takeaways All of this points towards these drugs being protective for a number of diseases, many of which are driven by inflammation, says Dr Cork

Keep your Male Excel products in a safe place to protect them

Congratulations to Eli Lilly and the broader obesity treatment community